Results 181 to 190 of about 118,970 (311)

Most-Favored-Nation Benchmarking Versus Value-Based Contracting: Institutional Fit of Pharmaceutical Pricing Tools in the United States, Canada, and the United Kingdom. [PDF]

Health Serv Insights
Adegoke K, Durojaye OA, Adegoke A, Adegoke A.   +3 more
europepmc   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

A Model of Incentive Compatibility under Moral Hazard in Livestock Disease Outbreak Response

This paper uses a principal-agent model to examine incentive compatibility in the presence of information asymmetry between the government and individual producers.
Horan, Richard D., Gramig, Benjamin M., Wolf, Christopher A.   +2 more
core  

Incentive-Compatible Adjustments from the Anchor and Correlated Equilibrium / Ajustements depuis l’ancrage compatibles avec les incitations et équilibre corrélé [PDF]

In repeated-round auction mechanisms with endogenous market-clearing prices, i.e. when prices depend on submitted bids, the assumption of independent private values that underlines the property of incentive-compatibility is to be brought into question ...
Arnaud Dragicevic
core  

The benefits of in situ reporting: Experimental evidence from in-the-moment surveys of public transit riders. [PDF]

Behav Res Methods
Antoun C, Frías-Martínez V, Garove A, Awasthi N, Abrar SM.   +4 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Incentive Pay Systems and the Management of Human Resources in France and Great Britain [PDF]

Incentive pay systems have undergone major changes in recent decades. This paper investigates use of incentive pay systems in British and French private sector establishments in 2004, focusing on payment-by-results, merit pay, and profit sharing, using ...
Salima Benhamou, Richard Belfield, David Marsden   +2 more
core  

Environmental Aspects in Price and Reimbursement Decisions of Medicines-A Scoping Review. [PDF]

Basic Clin Pharmacol Toxicol
Alajärvi L, Miettinen M, Timonen J.
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Financial incentives for women's cervical, breast and colorectal cancer screening adherence: systematic review and meta-analysis. [PDF]

Prev Med Rep
Lumia C, Nespoli A, Ausili D, Fumagalli S, Dumont A.   +4 more
europepmc   +1 more source